Non-pegylated liposomal doxorubicin (Myocet)
Jump to navigation
Jump to search
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
General information
Class/mechanism: A formulation of the citrate salt of the antineoplastic anthracycline antibiotic doxorubicin, encapsulated within liposomes, with antitumor activity.
Diseases for which it is used
History of changes in EMA indication
- 2000-07-13: Initial marketing authorization as Myocet.
- Uncertain date: Myocet liposomal, in combination with cyclophosphamide, is indicated for the first-line treatment of metastatic breast cancer in adult women.
Also known as
- Generic names: liposome-encapsulated doxorubicin citrate, NPLD
- Brand name: Myocet